{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:37:23Z","timestamp":1787801843745,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.addbeh.2022.107589","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:53:43Z","timestamp":1671274423000},"page":"107589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"139","author":[{"given":"Catherine","family":"Baxley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Borsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill V.","family":"Reavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Batki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Seal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s13063-018-3055-z","article-title":"Single high-dose buprenorphine for opioid craving during withdrawal","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.addbeh.2022.107589_b0010","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2004.05.002","article-title":"Opioid detoxification using high doses of buprenorphine in 24 hours: A randomized, double blind, controlled clinical trial","volume":"27","author":"Assadi","year":"2004","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.addbeh.2022.107589_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/00952990.2011.596982","article-title":"Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial","volume":"37","author":"Back","year":"2011","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1037\/pha0000215","article-title":"The influence of anxiety sensitivity on opioid use disorder treatment outcomes","volume":"27","author":"Baxley","year":"2019","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"10182","key":"10.1016\/j.addbeh.2022.107589_b0030","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.addbeh.2022.107589_b0035","unstructured":"Center for Substance Abuse Treatment (2004). SAMHSA\/CSAT treatment improvement protocols. In Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Substance Abuse and Mental Health Services Administration (US)."},{"key":"10.1016\/j.addbeh.2022.107589_b0040","unstructured":"Centers for Disease Control and Prevention (2021, November 17). Drug Overdose Deaths in the U.S. Top 100,000 Annually. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm#:\u223c:text=Provisional%20data%20from%20CDC's%20National,same%20period%20the%20year%20before."},{"key":"10.1016\/j.addbeh.2022.107589_b0045","unstructured":"DistillerSR (2021). DistillerSR: Literature review software (Version 2.35). Evidence Partners. https:\/\/www.evidencepartners.com."},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1360-0443.2001.961333.x","article-title":"Theories of drug craving, ancient and modern","volume":"96","author":"Drummond","year":"2001","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.addbeh.2022.107589_b0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.addbeh.2022.107589_b0065","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/00952990.2010.505991","article-title":"Heroin anticraving medications: A systematic review","volume":"36","author":"Fareed","year":"2010","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10550887.2010.531672","article-title":"Effect of methadone maintenance treatment on heroin craving, a literature review","volume":"30","author":"Fareed","year":"2010","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.addbeh.2022.107589_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.addbeh.2022.107589_b0080","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13311-019-00791-8","article-title":"Opioid craving in human laboratory settings: A review of the challenges and limitations","volume":"17","author":"Goodyear","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.addbeh.2022.107589_b0090","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: Study design: Randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG : An international journal of obstetrics and gynaecology"},{"key":"10.1016\/j.addbeh.2022.107589_b0095","series-title":"National heroin task force final report and recommendations","author":"Hickton","year":"2015"},{"key":"10.1016\/j.addbeh.2022.107589_b0100","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107589_b0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","volume":"36","author":"Jackson","year":"2015","journal-title":"Substance Abuse"},{"key":"10.1016\/j.addbeh.2022.107589_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107639","article-title":"Craving and opioid use disorder: A scoping review","volume":"205","author":"Kleykamp","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.addbeh.2022.107589_b0120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/0269881117711710","article-title":"Buprenorphine\/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals","volume":"31","author":"Law","year":"2017","journal-title":"Journal of Psychopharmacology"},{"issue":"10118","key":"10.1016\/j.addbeh.2022.107589_b0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.addbeh.2022.107589_b0130","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107589_b0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.addbeh.2022.107589_b0140","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.addbeh.2022.107589_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.addbeh.2022.107589_b0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.addbeh.2022.107589_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2019.05.034","article-title":"Stress and opioid use disorder: A systematic review","volume":"98","author":"MacLean","year":"2019","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.addbeh.2022.107589_b0160","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ajad.12344","article-title":"Cue-induced craving to paraphernalia and drug images in opioid dependence","volume":"25","author":"McHugh","year":"2016","journal-title":"American Journal on Addictions"},{"issue":"10","key":"10.1016\/j.addbeh.2022.107589_b0170","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1037\/ccp0000399","article-title":"Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction","volume":"87","author":"Messina","year":"2019","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"7","key":"10.1016\/j.addbeh.2022.107589_b0175","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"8","key":"10.1016\/j.addbeh.2022.107589_b0180","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.pnpbp.2008.08.019","article-title":"Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: Preliminary results of an open randomized study","volume":"32","author":"Nava","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","article-title":"Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction","volume":"38","author":"Neumann","year":"2020","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.addbeh.2022.107589_b0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addbeh.2014.09.021","article-title":"Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model","volume":"41","author":"Northrup","year":"2015","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107589_b0195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009\u20132018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","article-title":"Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior\u2014Outcomes of a randomized trial","volume":"133","author":"Otiashvili","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107589_b0210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00213-009-1472-0","article-title":"Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving","volume":"204","author":"Ren","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.addbeh.2022.107589_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108083","article-title":"Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017\u20132018: A cross-sectional study","volume":"213","author":"Roehler","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2022.107589_b0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cpr.2009.06.002","article-title":"Clinical and laboratory assessment of the subjective experience of drug craving","volume":"29","author":"Rosenberg","year":"2009","journal-title":"Clinical Psychology Review"},{"issue":"Suppl 2","key":"10.1016\/j.addbeh.2022.107589_b0225","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1046\/j.1360-0443.95.8s2.8.x","article-title":"The measurement of drug craving","volume":"95","author":"Sayette","year":"2000","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107589_b0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.neubiorev.2009.11.024","article-title":"Craving's place in addiction theory: Contributions of the major models","volume":"34","author":"Skinner","year":"2010","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.addbeh.2022.107589_b0235","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jsat.2010.05.014","article-title":"Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons","volume":"39","author":"Stein","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2022.107589_b0245","unstructured":"Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63 publication No. PEP21-02-01-002. Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.addbeh.2022.107589_b0250","doi-asserted-by":"crossref","unstructured":"Tanum, L., Solli, K. K., Latif, Z.-e.-H., Benth, J. \u0160., Opheim, A., Sharma-Haase, K., Krajci, P., & Kun\u00f8e, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry, 74(12), 1197-1205. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3206.","DOI":"10.1001\/jamapsychiatry.2017.3206"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"issue":"3","key":"10.1016\/j.addbeh.2022.107589_b0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0146-6402(92)90005-9","article-title":"A critique of contemporary urge and craving research: Methodological, psychometric, and theoretical issues","volume":"14","author":"Tiffany","year":"1992","journal-title":"Advances in Behaviour Research and Therapy"},{"issue":"4","key":"10.1016\/j.addbeh.2022.107589_b0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2011.03581.x","article-title":"Beyond drug use: A systematic consideration of other outcomes in evaluations of treatments for substance use disorders","volume":"107","author":"Tiffany","year":"2012","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.addbeh.2022.107589_b0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"issue":"2","key":"10.1016\/j.addbeh.2022.107589_b0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00952990.2013.848875","article-title":"Craving and subsequent opioid use among opioid dependent patients who initiate treatment with buprenorphine","volume":"40","author":"Tsui","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460322003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460322003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:51:26Z","timestamp":1759690286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460322003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":55,"alternative-id":["S0306460322003550"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2022.107589","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2022.107589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107589"}}